1P-LSD Stats - Substance Search

Receptor Profile

Receptor Actions

Agonists

5-HT2A receptor agonist (partial)

Other

prodrug of LSD (rapidly hydrolyzed to LSD in vivo)

History & Culture

1P-LSD emerged on the online research chemical market in late 2014 and early 2015, representing the first widely available 1-acylated lysergamide derivative. The compound was first synthesized by Lizard Labs, a Netherlands-based research chemical laboratory that had already established a reputation for producing high-quality novel psychedelics. It quickly became the laboratory's most well-known creation and was subsequently distributed through numerous other vendors worldwide. Prior to its commercial appearance, 1P-LSD had no documented history of human use and does not appear in any academic literature predating its emergence on the grey market. While its synthesis likely occurred in an academic context, the identity of its original discoverer remains unknown. The substance was marketed as a legal alternative to LSD, LSZ, and AL-LAD, typically sold in blotter form and labeled as a research chemical not intended for human consumption. Notably, the strategy of using 1-alkylated lysergamide derivatives to circumvent controlled substance laws was anticipated decades before 1P-LSD's arrival. A 1988 DEA report had foreseen that such structural modifications could be employed to bypass legislation that specifically banned LSD, making 1P-LSD's emergence something of a predicted inevitability within the research chemical community. Upon its release, users quickly recognized that its effects were virtually indistinguishable from those of LSD itself, contributing to its rapid adoption and widespread popularity.

Subjective Effects

Physical

Spontaneous tactile sensations: The body high of 1P-LSD can be described as proportionally very intense in comparison to its accompanying visual and cognitive effects. It behaves as a euphoric, fast moving, sharp and location specific tingling sensation. For some, it is manifested spontaneously at different unpredictable points throughout the trip, but for most it maintains a steady presence that rises with the onset and hits its limit once the peak has been reached. At moderate to high doses of 1P-LSD, this sensation will usually hit its highest level and become so overwhelming that people may find themselves writhing on the floor in complete pleasure.
Stimulation: In terms of its effects on the physical energy levels of the tripper, 1P-LSD is usually considered to be very energetic and stimulating without being forced. For example, when taken in any environment it will usually encourage physical activities such as running, walking, climbing or dancing. In comparison, other more commonly used psychedelics such as psilocin are generally sedating and relaxed.
Nausea: Mild nausea is occasionally reported when consumed in moderate to high dosages and either passes instantly once the tripper has vomited or gradually fades by itself as the peak sets in.
Tactile enhancement
Bodily control enhancement
Increased salivation
Increased heart rate
Pupil dilation

Cognitive

In comparison to other psychedelics such as psilocin, LSA and ayahuasca, 1P-LSD is significantly more stimulating and fast paced in terms of the specific style of thought stream produced and contains a large number of potential effects.

Current mind state enhancement
Thought acceleration
Novelty enhancement
Time distortion
Analysis enhancement
Personal bias suppression
Conceptual thinking
Memory suppression
Thought loops
Feelings of interdependent opposites
Delusions
Unity and interconnectedness
Feelings of self-design
Spirituality enhancement
Delineation of thought

Sensory

Auditory

Enhancements
Distortions
Hallucinations

Visual · Distortions

Visual drifting: (Melting, Breathing, Morphing and Flowing) - In comparison to other psychedelics, this effect can be described as highly detailed and cartoon-like in its appearance. The distortions are slow and smooth in motion and fleeting in their appearance.
Tracers
Depth perception distortions
Symmetrical texture repetition
Colour shifting
Perspective distortions

Visual · Enhancements

Visual acuity enhancement
Colour enhancement
Pattern recognition enhancement

Visual · Hallucinatory States

1P-LSD is capable of producing a full range of low and high level hallucinatory states in a fashion that is significantly less consistent and reproducible than that of many other commonly used psychedelics.

Transformations
Internal hallucinations: Although 1P-LSD is technically capable of producing hallucinatory states in a fashion that is on par with psilocin or DMT in its vividness and intensity, these effects are rarer and more inconsistent in comparison. While traditional psychedelics such as LSA, ayahuasca and mescaline will induce internal hallucinations near consistently at level 5 geometry and above, 1P-LSD will for most simply go straight into Level 8A visual geometry. This lack of consistently induced hallucinatory breakthroughs means that for most, 1P-LSD is not quite as deep of an experience as certain other psychedelics.

Forked from Subjective Effect Documentation by Josie Kins, March 2015. Via dose.wiki (CC0).

Toxicity

PsychonautWiki

The toxicity and long-term health effects of recreational 1P-LSD use have not been studied. This is because 1P-LSD is a research chemical with almost no history of human use. Anecdotal reports suggest that there are no negative health effects attributed to simply trying 1P-LSD by itself, at low to moderate doses, and using it very sparingly (although nothing can be completely guaranteed). Independent research should always be conducted to ensure that a combination of two or more substances is safe before consumption. Based on its similarity to LSD, 1P-LSD is assumed to be physiologically well-tolerated with a extremely low toxicity relative to dose.

Overdose

1P-LSD has no known toxic dose. However, higher doses increase the risk of adverse psychological reactions. These reactions include anxiety, delusions, panic attacks and, more rarely, seizures.

Addiction & dependence

Although no formal studies have been conducted, it is assumed that like LSD itself, 1P-LSD is non-addictive with a low abuse potential. There are no literature reports of successful attempts to train animals to self-administer LSD — an animal model predictive of abuse liability — indicating that it does not have the necessary pharmacology to either initiate or maintain dependence. Likewise, there is virtually no withdrawal syndrome when chronic use of LSD is stopped.

Effect Profile

Curated + 88 Reports

Psychedelic 8.8

Strong visuals, headspace, auditory effects, and body load

Visual Intensity×3

10102.9

Headspace Depth×3

10102.4

Auditory Effects×1

10101.1

Body Load / Somatic Effects×1

108.42.4

Catalog Erowid BlueLight

Based on reports from:

Effect Index Microcosms — nervewing Bluelight Big & Dandy Thread Erowid Experience Reports PsychonautWiki 1P-LSD The Drug Users Bible 1P-LSD

Community Effects

TripSit

Positive

euphoria visual enhancement introspection creativity music enhancement

Negative

anxiety nausea insomnia

Tolerance & Pharmacokinetics

drugs.wiki

Half-Life

Unknown for 1P‑LSD; LSD’s elimination half‑life is commonly reported around 3–5 hours, with prolonged receptor residence possibly contributing to long effects.

Addiction Potential

Low; not considered physically addictive. Psychological habituation possible with frequent or context‑driven use.

Tolerance Decay

Full tolerance 1d Half tolerance 7d Baseline ~14d

Rapid within‑session tachyphylaxis; re‑dosing the same day yields little additional effect. Substantial decay by ~7 days; near‑baseline at ~14 days for most, though individual variability exists.

Cross-Tolerances

LSD

other lysergamides

psilocybin/psilocin

Experience Report Analysis

Erowid BlueLight

112 Reports

57 Single-substance

2014–2025 Date Range

107 With Age Data

30 Effects Detected

Demographics

Gender Distribution

Age Distribution

Reports Over Time

Effect Analysis

Erowid + Bluelight

Effects aggregated from 88 experience reports (57 single-substance Erowid + 31 Bluelight)

88 Reports

143 Effects Detected

73 Positive

51 Adverse

19 Neutral

Effect Sentiment Distribution

Confidence Distribution

Each bar is the share of reports mentioning the effect; its whisker, and the band on the rows below, is the 95% interval: where the share could plausibly be with other reports of the same kind.

Positive Effects 73

Color Enhancement 60.2% 88%

Visual Distortions 54.5% 82%

Music Enhancement 48.9% 88%

Introspection 39.8% 83%

Empathy 33.0% 85%

Stimulation 31.8% 80%

Closed-Eye Visuals 31.8% 92%

Euphoria 28.4% 89%

Joy 22.6% 84%

Geometric Imagery 22.6% 87%

Visual Trails 19.4% 89%

Awe 19.4% 80%

Surface Breathing 16.1% 85%

Patterning 16.1% 88%

Insight 16.1% 76%

Morphing 16.1% 83%

Contentment 16.1% 79%

Mystical Quality 16.1% 83%

Tactile Enhancement 16.0% 85%

Body High 15.9% 81%

Adverse Effects 51

Anxiety 37.5% 84%

Confusion 29.5% 86%

Thought Disorganization 29.0% 74%

Fear 25.8% 88%

Panic 19.4% 85%

Nausea 17.1% 82%

Body Load 16.1% 82%

Muscle Tension 14.8% 75%

Sweating 12.9% 80%

Depersonalization 12.9% 84%

Entity Imagery 12.9% 82%

Insomnia 12.9% 88%

Pupil Dilation 12.5% 85%

Memory Suppression 12.5% 76%

Jaw Clenching 11.4% 90%

Thought Loops 11.4% 83%

Motor Impairment 10.3% 85%

Restlessness 9.7% 78%

Headache 9.1% 80%

⚠ Psychosis 7.0% 70%

Show 31 more adverse effects

Paranoia 6.5% 82%

Loneliness 6.5% 72%

Sociability Suppression 6.5% 75%

Temporal Disorientation 6.5% 88%

Vomiting 6.5% 82%

Blurred Vision 3.2% 85%

Dry Mouth 3.2% 75%

Dizziness 3.2% 80%

Metallic Taste 3.2% 85%

Auditory Echo 3.2% 85%

Environmental Transfiguration 3.2% 85%

Skin Crawling 3.2% 85%

Dysphoria 3.2% 90%

Dehydration 3.2% 75%

Clammy 3.2% 75%

Near-Death Experience 3.2% 75%

Derealization 3.2% 85%

Identity Confusion 3.2% 90%

Body Distortion 3.2% 85%

Disrupted Sleep Architecture 3.2% 80%

Focus Suppression 3.2% 75%

Pain Enhancement 3.2% 90%

Stomach Cramps 3.2% 65%

Ataxia 3.2% 75%

Chills 3.2% 75%

Sexual Change 3.2% 65%

Hot Flashes 3.2% 90%

Cold Flashes 3.2% 90%

Temperature Dysregulation 3.2% 95%

Time Disorientation 3.2% 85%

Amnesia 3.2% 80%

Dose-Response Correlation

How effect frequency changes across dose levels. Whiskers, and the numbers' hover text, give each figure's 95% interval.

Not drawn, too few reports (a dose tier needs 20): Oral Common (n=14). Why 20?

Dosage Distribution

Dose distribution from experience reports, one dose per report (the first listed). Values above Q3 + 3×IQR are left out as outliers.

Sublingual

Median: 100.0 µg IQR: 100.0–152.5 µg n=16 2 outliers left out

Oral

Median: 100.0 µg IQR: 100.0–200.0 µg n=40 2 outliers left out

Real-World Dose Distribution

62K Doses

From 135 individual dose entries. Values above Q3 + 3×IQR are left out as outliers.

Sublingual (n=41)

Median: 0.1mg 25th: 0.05mg 75th: 0.15mg 90th: 0.2mg

Oral (n=63)

Median: 0.1mg 25th: 0.05mg 75th: 0.2mg 90th: 0.3mg

Common Combinations

Most co-occurring substances, as a share of all 112 reports filed under 1P-LSD; whiskers are 95% intervals

Form / Preparation

Most common forms and preparations, as a share of the 88 reports that give one; whiskers are 95% intervals

Body-Weight Dosing

Dose per kg of body weight, one dose per report (the first listed), from reports giving a weight of 30–250 kg. Values above Q3 + 3×IQR are left out as outliers.

Sublingual

Median: 0.002 mg/kg IQR: 0.001–0.002 mg/kg n=17 1 outlier left out

Oral

Median: 0.002 mg/kg IQR: 0.001–0.003 mg/kg n=39 1 outlier left out

Unknown

Median: 0.002 mg/kg IQR: 0.001–0.002 mg/kg n=9

Redose Patterns

Redosing behavior across 90 reports

18.9% Redosed

1.2 Avg Doses

60m Median Interval

Legal Status

Not scheduled under the UN Convention on Psychotropic Substances

Country	Status	Notes
Australia	Prohibited	Classified as a controlled substance under national drug legislation.
Austria	Grey area	Not explicitly scheduled but may fall under the NPSG (Neue-Psychoaktive-Substanzen-Gesetz) as a structural analogue of LSD, making supply for human consumption potentially illegal.
Canada	Unscheduled	Not specifically listed in the Controlled Drugs and Substances Act. However, sale or possession for human consumption could potentially be prosecuted under analogue provisions.
Croatia	Controlled	Listed as a prohibited substance under national drug control legislation.
Czech Republic	Controlled	Classified as a controlled substance since January 1, 2014.
Denmark	Illegal	Explicitly named on the list of controlled substances as of August 25, 2015.
Estonia	Schedule I (ainete I)	Controlled as a Schedule I substance since June 1, 2017.
Finland	Controlled	Classified as a controlled substance since November 15, 2018.
France	Prohibited	Listed as a controlled substance under national drug legislation.
Germany	NpSG controlled	Regulated under the Neue-psychoaktive-Stoffe-Gesetz (New Psychoactive Substances Act) since July 18, 2019. Production, import for market distribution, administration to others, and trading are criminal offenses. Personal possession is prohibited but not subject to criminal penalty.
Italy	Tabella I (Schedule I)	Classified as a Schedule I controlled substance under Italian drug legislation.
Japan	Controlled	Listed as a controlled substance under national drug control laws.
Latvia	Illegal	Controlled as a structural analogue of LSD following an amendment to drug scheduling that took effect June 1, 2015. Not explicitly named but covered under analogue provisions.
Lithuania	Illegal	Explicitly named on the list of controlled substances since September 21, 2015.
Norway	Controlled	Classified as a controlled substance since February 14, 2013.
Romania	Controlled	Listed as a controlled substance under national drug legislation.
Russia	Illegal	Prohibited since 2017 as a derivative of LSD under national drug control laws.
Singapore	Class A	Classified as a Class A controlled substance, carrying severe penalties for possession, trafficking, and distribution.
Sweden	Illegal	Specifically scheduled following its emergence as a designer drug. Prohibition took effect January 26, 2016.
Switzerland	Verzeichnis E	Explicitly named under Verzeichnis E of controlled substances since December 2015.
Turkey	Illegal	Prohibited under national drug control legislation since February 2016.
United Kingdom	Illegal (Psychoactive Substances Act)	Production, supply, and import prohibited under the Psychoactive Substances Act 2016, which came into effect May 26, 2016. This blanket legislation covers psychoactive substances not specifically exempted.
United States	Unscheduled (Analogue Act applies)	Not explicitly scheduled under the Controlled Substances Act. However, as a prodrug of LSD, possession and sale intended for human consumption may be prosecuted under the Federal Analogue Act, which treats substantially similar compounds as Schedule I substances.

Harm Reduction

drugs.wiki

1P‑LSD first appeared circa 2014–2015 and is widely believed to act as a prodrug for LSD: incubation in human serum yields LSD, and subjective time‑course is near‑identical to LSD for most users. Start low because potency equivalence to LSD varies across labs/batches and human data are mixed; community surveys tend to find similar duration and slightly weaker average strength than LSD, but animal HTR potency is lower and inter‑batch variability is large. Blotter dose labels are often imprecise; consider that actual content may deviate ±15–30%. Reagent testing: 1‑acyl lysergamides may show a delayed/weak Ehrlich reaction (pink to light purple over 15–30+ minutes); use a clean ceramic surface, pre‑wet the blotter with a drop of water, and prefer multi‑reagent or laboratory drug checking where available; note that adulteration with tryptamine has been used to fake Ehrlich‑positive results. Redosing the same day is typically inefficient due to rapid 5‑HT2A tolerance; spacing at least 2 weeks between sessions helps restore sensitivity. Avoid mixing with lithium or TCAs due to consistent reports of severe reactions and seizures; if you take prescription psychoactives, consult a clinician. Plan set/setting, have a trusted sober sitter for higher doses, and avoid unsafe environments; impairments can persist into the next day—do not drive or operate machinery until fully baseline. Store blotters airtight, light/heat/oxygen protected (foil, desiccant, cold), to limit degradation and inadvertent hydrolysis to LSD over time. People with a personal or family history of psychosis or bipolar disorder should avoid serotonergic psychedelics due to elevated risk of adverse psychiatric events.

1P-LSD Stats & Data

Receptor Profile

Receptor Actions

History & Culture

Subjective Effects

Physical

Cognitive

Sensory

Toxicity

Overdose

Addiction & dependence

Effect Profile

Community Effects

Tolerance & Pharmacokinetics

Tolerance Decay

Cross-Tolerances

Experience Report Analysis

Demographics

Gender Distribution

Age Distribution

Reports Over Time

Effect Analysis

Effect Sentiment Distribution

Confidence Distribution

Positive Effects 73

Adverse Effects 51

Dose-Response Correlation

Dosage Distribution

Sublingual

Oral

Real-World Dose Distribution

Sublingual (n=41)

Oral (n=63)

Common Combinations

Form / Preparation

Body-Weight Dosing

Sublingual

Oral

Unknown

Redose Patterns

Legal Status

Harm Reduction

References

Data Sources

Cited References

Additional references